Patents by Inventor Galia Blum

Galia Blum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11344634
    Abstract: Provided is a compound including at least one carrier moiety associated with a plurality of CT imaging moieties, and with at least one enzyme interacting moiety as well as uses thereof in diagnosis.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: May 31, 2022
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Galia Blum, Darya Tsivrkun, Hanmant Gaikwad
  • Publication number: 20190054035
    Abstract: Provided are peptide-based nanostructures, as well as diagnostic and therapeutic methods using same.
    Type: Application
    Filed: April 10, 2018
    Publication date: February 21, 2019
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Galia BLUM, Yael BEN-NUN, Ehud GAZIT, Lihi ADLER-ABRAMOVICH, Galit FICHMAN
  • Publication number: 20190054193
    Abstract: Provided is a compound including at least one carrier moiety associated with a plurality of CT imaging moieties, and with at least one enzyme interacting moiety as well as uses thereof in diagnosis.
    Type: Application
    Filed: February 16, 2017
    Publication date: February 21, 2019
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Galia BLUM, Darya TSIVRKUN, Hanmant GAIKWAD
  • Patent number: 8968700
    Abstract: Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes employ an acyloxymethyl ketone reactive group, one or more amino acids for determining specificity, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY7 (diarylyrhodamine) quencher and a BODIPY (bora-diaza-indecene) dye.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: March 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew S. Bogyo, Galia Blum, Georges von Degenfeld
  • Patent number: 8343458
    Abstract: Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as 64Cu, 125I (SPECT) and 99mTc (PET). The probes show in vivo half-life and stability well suited for imaging.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: January 1, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew S. Bogyo, Galia Blum, Alicia Berger, Zhen Cheng, Sanjiv S. Gambhir
  • Publication number: 20090252677
    Abstract: Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as 64Cu, 125I (SPECT) and 99mTc (PET). The probes show in vivo half-life and stability well suited for imaging.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 8, 2009
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew S. Bogyo, Galia Blum, Alicia Berger, Zhen Cheng, Sanjiv S. Gambhir
  • Publication number: 20070036725
    Abstract: Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes employ an acyloxymethyl ketone reactive group, one or more amino acids for determining specificity, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY7 (diarylyrhodamine) quencher and a BODIPY (bora-diaza-indecene) dye.
    Type: Application
    Filed: August 10, 2006
    Publication date: February 15, 2007
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew Bogyo, Galia Blum, Georges von Degenfeld
  • Publication number: 20050143430
    Abstract: The present invention provides catechol bioisostere compounds which are potent inhibitors of protein tyrosine kinases (PTKs). The present invention further provides methods of inhibiting PTKs, for example receptor protein tyrosine kinases (RTKs), comprising administering the catechol bioisosteres. The catechol bioisostere compounds are useful in treating or preventing PTK-related disease states, particularly protein tyrosine kinase related disorders which are associated with defects in signaling pathways mediated by PTKs.
    Type: Application
    Filed: August 5, 2004
    Publication date: June 30, 2005
    Inventors: Aviv Gazit, Alexander Levitzki, Galia Blum